Premium
Crosstalk between myeloid‐derived suppressor cells and the immune system in prostate cancer
Author(s) -
Sanaei MohammadJavad,
Salimzadeh Loghman,
Bagheri Nader
Publication year - 2020
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.4ru0819-150rr
Subject(s) - prostate cancer , biology , cancer research , myeloid derived suppressor cell , immune system , cancer , suppressor , stat3 , immunology , prostate , myeloid , crosstalk , population , cancer cell , signal transduction , medicine , microbiology and biotechnology , genetics , physics , environmental health , optics
Prostate cancer is the second most common cancer and the fifth leading cause of cancer‐associated death in men. Previous studies have revealed a surprising ability for an immature population of myeloid cells called myeloid‐derived suppressor cells (MDSCs) in the commencement and development of many tumors, including those of prostate cancer. Herein, the molecular and cellular changes of MDSCs in prostate cancer in both human and nonhuman models are reviewed. The suppressive function of MDSCs are also discussed with a particular focus on the role of IL‐6 and JAK/STAT3 signaling pathways in the induction of their suppressive activity. Ultimately, a brief review of MDSC‐targeting approaches for potential cancer therapy is presented.